Therapeutics
PF-06852231
Quick Links
Overview
Name: PF-06852231
Therapy Type: Small Molecule (timeline)
Target Type: Cholinergic System (timeline)
Condition(s): Alzheimer's Disease
U.S. FDA Status: Alzheimer's Disease (Discontinued)
Company: Pfizer
Background
PF-06852231 is a small-molecule cholinergic modulator. No preclinical information about this compound is published.
Findings
In July 2017, Pfizer began enrolling healthy volunteers for a safety, tolerability, and pharmacokinetics study of this compound at the company's clinical research unit in Brussels. In January 2018, Pfizer announced it was discontinuing its research and development work across neuroscience indications, and this compound was discontinued.
As of January 31, 2018, clinicaltrials.gov still showed this trial as enrolling; however, the Pfizer Pipeline of January 30, 2018, lists it as discontinued.
Last Updated: 02 Feb 2018
References
External Citations
Further Reading
No Available Further Reading
Comments
No Available Comments
Make a Comment
To make a comment you must login or register.